The_DT
candidate_NN
oncoprotein_NN
Bcl-3_NN
is_VBZ
an_DT
antagonist_NN
of_IN
p50\/NF-kappa_NN
B-mediated_JJ
inhibition_NN
._.

The_DT
candidate_NN
oncogene_NN
bcl-3_NN
was_VBD
discovered_VBN
as_IN
a_DT
translocation_NN
into_IN
the_DT
immunoglobulin_NN
alpha-locus_NN
in_IN
some_DT
cases_NNS
of_IN
B-cell_NN
chronic_JJ
lymphocytic_JJ
leukemias_NNS
._.

The_DT
protein_NN
Bcl-3_NN
contains_VBZ
seven_CD
so-called_JJ
ankyrin_NN
repeats_NNS
._.

Similar_JJ
repeat_NN
motifs_NNS
are_VBP
found_VBN
in_IN
a_DT
number_NN
of_IN
diverse_JJ
regulatory_JJ
proteins_NNS
but_CC
the_DT
motifs_NNS
of_IN
Bcl-3_NN
are_VBP
most_RBS
closely_RB
related_JJ
to_TO
those_DT
found_VBN
in_IN
I_CD
kappa_NN
B_NN
proteins_NNS
in_IN
which_WDT
the_DT
ankyrin_NN
repeat_NN
domain_NN
is_VBZ
thought_VBN
to_TO
be_VB
directly_RB
involved_VBN
in_IN
inhibition_NN
of_IN
NF-kappa_NN
B_NN
activity_NN
._.

No_DT
biological_JJ
function_NN
has_VBZ
yet_RB
been_VBN
described_VBN
for_IN
Bcl-3_NN
,_,
but_CC
it_PRP
was_VBD
noted_VBN
recently_RB
that_IN
Bcl-3_NN
interferes_VBZ
with_IN
DNA-binding_NN
of_IN
the_DT
p50_NN
subunit_NN
of_IN
NF-kappa_NN
B_NN
in_FW
vitro_FW
._.

Here_RB
we_PRP
demonstrate_VBP
that_IN
Bcl-3_NN
can_MD
aid_VB
kappa_NN
B_NN
site-dependent_JJ
transcription_NN
in_FW
vivo_FW
by_IN
counteracting_VBG
the_DT
inhibitory_JJ
effects_NNS
of_IN
p50\/NF-kappa_NN
B_NN
homodimers_NNS
._.

Bcl-3_NN
may_MD
therefore_RB
aid_VB
activation_NN
of_IN
select_JJ
NF-kappa_NN
B-regulated_JJ
genes_NNS
,_,
including_VBG
those_DT
of_IN
the_DT
human_JJ
immunodeficiency_NN
virus_NN
._.

